Gemtuzumab Ozogamicin represents a significant development in the treatment of acute blood leukemia, specifically aggressive blood cancer (AML). This particular medication links a targeted immunoglobulin aimed for the CD33 antigen found on leukemic populations with a cytotoxic payload, resulting in cell-specific cytotoxicity. As a result, it a p… Read More